



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/823,999	03/20/97	ROGERS	MIT/501

PATREA L. PABST
ARNALL GOLDEN & GREGORY
2800 ONE ATLANTIC CENTER
1201 W. PEACHTREE STREET
ATLANTA GA 30309-3450

HM11/1229

#17

EXAMINER
GAMBEL, F

ART UNIT	PAPER NUMBER
1644	

DATE MAILED: 12/29/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

08/843 999

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
		11/11/1999	1644

RECEIVED
PATENT & TRADEMARK OFFICE
AUG 11 1999

EXAMINER	
ART UNIT	PAPER NUMBER
	17

DATE MAILED:

Below is a communication from the EXAMINER in charge of this application

COMMISSIONER OF PATENTS AND TRADEMARKS

ADVISORY ACTION

☒ THE PERIOD FOR RESPONSE:

- a) ☒ is extended to run _____ or continues to run 4 MONTHS from the date of the final rejection
- b) ☐ expires three months from the date of the final rejection or as of the mailing date of this Advisory Action, whichever is later. In no event however, will the statutory period for the response expire later than six months from the date of the final rejection.

Any extension of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate fee. The date on which the response, the petition, and the fee have been filed is the date of the response and also the date for the purposes of determining the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR 1.17 will be calculated from the date of the originally set shortened statutory period for response or as set forth in b) above.

☐ Appellant's Brief is due in accordance with 37 CFR 1.192(a).

☒ Applicant's response to the final rejection, filed 11/19/99, 14/3/99 has been considered with the following effect, but it is not deemed to place the application in condition for allowance:

1. ☒ The proposed amendments to the claim and/or specification will not be entered and the final rejection stands because:

- a) ☐ There is no convincing showing under 37 CFR 1.116(b) why the proposed amendment is necessary and was not earlier presented.
- b) ☒ They raise new issues that would require further consideration and/or search. (See Note).
- c) ☐ They raise the issue of new matter. (See Note).
- d) ☒ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal.
- e) ☐ They present additional claims without cancelling a corresponding number of finally rejected claims.

NOTE: GIVEN ENTRY OF AMO FILED 11/19/99 (PAPER NO. 15)
PROPER AMENDMENT TO CLAIMS, FILED 12/3/99, LACK
PROPER AMENDMENTS BUT BASIS
SEE MPEP 714.22; 37 CFR 1.121

2. ☐ Newly proposed or amended claims _____ would be allowed if submitted in a separately filed amendment cancelling the non-allowable claims.

3. ☒ Upon the filing an appeal, the proposed amendment ☒ will be entered ☐ will not be entered and the status of the claims will be as follows:

Claims allowed: _____
Claims objected to: _____
Claims rejected: 1-6, 8, 10-12

However;

☐ Applicant's response has overcome the following rejection(s): _____

4. ☒ The affidavit, exhibit or request for reconsideration has been considered but does not overcome the rejection because FOR THE REASONS OF REASON; SIMON (ARTICLE THROMBOLYTIC) AND
HYDROLYZABLE (ANN. PHARMACOL 1996) SUPPORT INHIBITING RESPONSES

5. ☐ The affidavit or exhibit will not be considered because applicant has not shown good and sufficient reasons why it was not earlier presented. THROMBOLYTIC REJECTION'S MAINTAINED

☐ The proposed drawing correction ☐ has ☐ has not been approved by the examiner.
12 IS MAINTAINED (APPLICANT'S REASONS ON SINGLE UNDISCLOSED SPECIES
IN SIMON ET AL CIRCULATION 1999. EXHIBIT) DOES NOT SUPPORT
BREATH OF CLAIMS COMPOUNDS MOLECULES, PEPTIDOMIMETICS

PHARM. GONADOL
ART UNIT 1644
12/19/99

Christina Chan
CHRISTINA Y. CHAN
SUPERVISORY PATENT EXAMINER
GROUP 1800-1660

BEST AVAILABLE COPY